Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment
NCT ID: NCT05797558
Last Updated: 2025-04-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-28
Study Completion Date
2028-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective randomized controlled trial where quality of life and the effectiveness of treatment will be evaluated in 80 patients with confirmed unilateral primary aldosteronism ,randomly assigned to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)
NCT04461535
Primary Aldosteronism
COMPLETED
NA
Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure
NCT01847690
Addison Disease
UNKNOWN
PHASE2
The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism
NCT06381323
Primary Aldosteronism
Finerenone
Mineralocorticoid Receptor Antagonist
COMPLETED
PHASE4
Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
NCT05826080
Primary Aldosteronism
Aldosterone-Producing Adenoma
Idiopathic Hyperaldosteronism
UNKNOWN
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
NCT06229405
Adrenal Tumor
Primary Aldosteronism
Cushing Syndrome
+2 more
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
Primary aldosteronism (PA) is caused by hypersecretion of the adrenal hormone aldosterone and is the most common cause of secondary hypertension . The estimated prevalence of PA is 5-13% in the hypertensive population.
In half of the cases, PA is caused by unilateral hypersecretion of aldosterone, most commonly from an aldosterone producing adenoma. Overproduction from both adrenals is seen in the other half, usually caused by bilateral idiopathic hyperplasia. Unilateral adrenalectomy is considered to be the treatment of choice for unilateral PA and mineralocorticoid receptor antagonists (MRAs, i.e. spironolactone or eplerenone) for bilateral PA . Untreated PA is associated with a greatly increased risk for several comorbidities, especially cardiovascular diseases and renal failure, as well as death.
Studies comparing surgical and medical treatment for PA are scarce. Nevertheless, a recent meta-analysis indicated that cardiovascular outcome is better in surgically than medically treated patients . In addition, quality of life seems to improve more after surgery, and the need for antihypertensive medications, and overall health care consumption,seems to be lower following surgery . However, suboptimal dosing of MRA is common in medically treated patients with PA, which makes a fair comparison between surgically treated patients difficult.
To identify candidates for surgical treatment, adrenal venous sampling (AVS) is necessary to confirm unilateral disease . However, AVS is a technically demanding procedure, with a mean success rate in non-specialized centres of only 32% . This, and the fact that AVS is not widely available, suggests that a substantial number of patients with unilateral PA are never identified and thereby not considered for surgical treatment .
Rationale, aim and hypotheses
Given the above, medical treatment with MRA has become the de-facto standard treatment for a large number of patients with unilateral PA, despite observational studies indicating that surgical treatment is more effective in terms of improving cardiovascular outcome, quality of life and drug load, and that it is more cost-effective.
In this context the investigators have designed a prospective randomized controlled trial where we aim to compare medical and surgical treatment for unilateral PA. The investigator´s main hypothesis is that surgical treatment (adrenalectomy; standard treatment) results in better QoL at one year of follow-up compared to medical treatment with eplerenone (intervention) in patients with unilateral PA.
The secondary hypotheses are: Surgical treatment is more effective than medical treatment for unilateral PA regarding a) antihypertensive effect, b) improvement in cardiometabolic risk profile, and c) health care consumption (cost-efficiency).
Study Design
The UPA-MEST (Unilateral Primary Aldosteronism - MinEralocorticoid antagonists versusSurgical Treatment) study is an unblinded, prospective, randomized, controlled trial. Eighty patients will be randomized to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone. After 12 months of follow-up, medically treated patients will be able to either continue with medical treatment or to be operated with unilateral adrenalectomy.
Participants
80 patients with confirmed unilateral PA, aged 18-70 will participate.
Inclusion and randomization
After unilateral PA has been confirmed, when the patients will be informed about the disease, the patients will be informed orally, and with written information about the study, and asked to participate.
Randomization will be done with random permutated blocks, generated by using a freely available software (www.randomizer.org).
Treatments
Surgical treatment: Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference. Potassium substitution \> 7.5 g will be reduced by 50% on postoperative day (POD) 1, and discontinued on POD 2. Potassium substitution \< 7.5 g will be discontinued on POD 1. Preoperative antihypertensive medication will be titrated to a goal blood pressure of 140/90 mmHg (14) or lower. Immunohistochemical method, using monoclonal antibodies identifying the enzymes CYP11B1 and B2, will be used to differentiate between adenoma and hyperplasia.
Medical treatment: The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily. During eplerenone dose titration, the doses of other antihypertensive medications will be reduced or, if possible, discontinued. Also, potassium replacement should be discontinued. In patients who develop significant hyperkalemia (\>4.6 mmol/L), the first step is to discontinue ACE inhibitors and/or angiotensin II receptor blocker (ARB). In patients not receiving treatment with ACE inhibitors or ARB, the dose of eplerenone will be decreased by 25-50 mg per day. Similarly, patients on monotherapy with eplerenone who develop very high renin concentrations and/or symptomatic hypotension, the dose of eplerenone should be decreased by 25-50 mg per day. Patients who do not attain optimal blood pressure on the maximal eplerenone dose will continue with other antihypertensive medications. It is expected that creatinine will increase in some patients, reflecting diminished renal hyperfiltration that is characteristic for patients with untreated PA. In these cases, the eplerenone dose should not be automatically reduced, and should only be considered in cases with severely worsening GFR (\>1.5 from the baseline value).
Follow-up
Total follow-up time is 24 months. For patients in the MRA arm, there will be a possibility to cross over (opt for surgery) after 12 months. The participants will be followed on at least 7 occasions throughout the study.
Outcome measures
Primary endpoint: The primary endpoint is the difference in improvement of QoL between surgically and medically treated patients at 12 months, measured with EQ5D (total score and the VAS scale).
Secondary endpoints: The secondary endpoints are: 1) Difference in improvement of QoL at 24 months, evaluated with EQ5D, 2) Difference in improvement of QoL at 12 and 24 months, evaluated with the SF-36/RAND-36 questionnaire, 3) The proportion of patients with complete, partial, and absent success of clinical and biochemical outcomes (based on blood pressure, use of antihypertensive drugs, plasma potassium, plasma renin and plasma aldosterone 1) according to the PASO criteria (15) at 12 and 24 months, 4) cardiovascular risk profile at 12 and 24 months, 5) difference in left ventricular mass on echocardiography at 12 and 24 months, 6) difference in renal function, evaluated by measuring eGFR and urinaryalbumin excretion at 12 and 24 months, and 7) total societal cost
Statistics and power calculation
Difference in treatment effects between the two groups will be analysed with paired t-test and Fishers exact test, as well as regression analyses with adjustments for age, gender, duration ofhypertension, as well as blood pressure and number of antihypertensive drugs at baseline.
For power calculation we used quality of life data from Velema et al. (EQ-5D) and Ahmedet al. (RAND SF-36) . With a significance level of 5% and power of 80%, inclusion of 50-54 subjects is needed (25-27 subjects in each treatment arm) to detect a difference betweensurgically and medically treated patients. Allowing for a 20% drop out rate, inclusion is set to 80 subjects (i.e. 40 in each treatment arm).
To ensure external validity, a screening log will be kept at each centre.
Clinical benefits
Contemporary treatment guidelines advocate surgical treatment in patients with unilateral disease. However, since AVS is not always successful, and not widely available, life-long medical treatment is often preferred for patients with PA, without any attempts to find out if they are candidates for curative surgical treatment. It is therefore of great importance to investigate if medical treatment is as effective as surgery in these patients. Currently, a head to head comparison of surgical versus medical treatments for patients with unilateral PA is lacking.
If it turns out that medical treatment is as efficient and safe as surgical treatment for patients with unilateral dominant disease, a large number of patients worldwide will benefit from the study. This concerns patients treated at centres where AVS is not available, patients where the AVS has not been successful as well as patients with unilateral dominant PA who are not considered candidates for surgical intervention. Thus, the study's results have a great potential to be quickly implemented in clinical practice.
Ethical considerations
The main ethical issue to acknowledge is that half of the patients will be randomized to receive medical treatment, i.e. they will not receive surgical treatment that is currently considered to be standard of care for unilateral PA. However, the reasons for considering the trial to be ethical are: a) Medical treatment with mineralocorticoid receptor antagonist forpatients with bilateral PA is effective and safe, b) Thorough information about the study willbe provided before participation, c) Participation is voluntary, d) After 12 months, all medically treated patients will have the option to receive surgical treatment i.e. adrenalectomy.
The study was approved by the Regional Research Ethics Committee in Gothenburg, Sweden on June 3rd, 2020 (DNR 2020-02008).
Primary aldosteronism (PA) is caused by hypersecretion of the adrenal hormone aldosterone and is the most common cause of secondary hypertension . The estimated prevalence of PA is 5-13% in the hypertensive population.
In half of the cases, PA is caused by unilateral hypersecretion of aldosterone, most commonly from an aldosterone producing adenoma. Overproduction from both adrenals is seen in the other half, usually caused by bilateral idiopathic hyperplasia. Unilateral adrenalectomy is considered to be the treatment of choice for unilateral PA and mineralocorticoid receptor antagonists (MRAs, i.e. spironolactone or eplerenone) for bilateral PA . Untreated PA is associated with a greatly increased risk for several comorbidities, especially cardiovascular diseases and renal failure, as well as death.
Studies comparing surgical and medical treatment for PA are scarce. Nevertheless, a recent meta-analysis indicated that cardiovascular outcome is better in surgically than medically treated patients . In addition, quality of life seems to improve more after surgery, and the need for antihypertensive medications, and overall health care consumption,seems to be lower following surgery . However, suboptimal dosing of MRA is common in medically treated patients with PA, which makes a fair comparison between surgically treated patients difficult.
To identify candidates for surgical treatment, adrenal venous sampling (AVS) is necessary to confirm unilateral disease . However, AVS is a technically demanding procedure, with a mean success rate in non-specialized centres of only 32% . This, and the fact that AVS is not widely available, suggests that a substantial number of patients with unilateral PA are never identified and thereby not considered for surgical treatment .
Rationale, aim and hypotheses
Given the above, medical treatment with MRA has become the de-facto standard treatment for a large number of patients with unilateral PA, despite observational studies indicating that surgical treatment is more effective in terms of improving cardiovascular outcome, quality of life and drug load, and that it is more cost-effective.
In this context the investigators have designed a prospective randomized controlled trial where we aim to compare medical and surgical treatment for unilateral PA. The investigator´s main hypothesis is that surgical treatment (adrenalectomy; standard treatment) results in better QoL at one year of follow-up compared to medical treatment with eplerenone (intervention) in patients with unilateral PA.
The secondary hypotheses are: Surgical treatment is more effective than medical treatment for unilateral PA regarding a) antihypertensive effect, b) improvement in cardiometabolic risk profile, and c) health care consumption (cost-efficiency).
Study Design
The UPA-MEST (Unilateral Primary Aldosteronism - MinEralocorticoid antagonists versusSurgical Treatment) study is an unblinded, prospective, randomized, controlled trial. Eighty patients will be randomized to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone. After 12 months of follow-up, medically treated patients will be able to either continue with medical treatment or to be operated with unilateral adrenalectomy.
Participants
80 patients with confirmed unilateral PA, aged 18-70 will participate.
Inclusion and randomization
After unilateral PA has been confirmed, when the patients will be informed about the disease, the patients will be informed orally, and with written information about the study, and asked to participate.
Randomization will be done with random permutated blocks, generated by using a freely available software (www.randomizer.org).
Treatments
Surgical treatment: Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference. Potassium substitution \> 7.5 g will be reduced by 50% on postoperative day (POD) 1, and discontinued on POD 2. Potassium substitution \< 7.5 g will be discontinued on POD 1. Preoperative antihypertensive medication will be titrated to a goal blood pressure of 140/90 mmHg (14) or lower. Immunohistochemical method, using monoclonal antibodies identifying the enzymes CYP11B1 and B2, will be used to differentiate between adenoma and hyperplasia.
Medical treatment: The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily. During eplerenone dose titration, the doses of other antihypertensive medications will be reduced or, if possible, discontinued. Also, potassium replacement should be discontinued. In patients who develop significant hyperkalemia (\>4.6 mmol/L), the first step is to discontinue ACE inhibitors and/or angiotensin II receptor blocker (ARB). In patients not receiving treatment with ACE inhibitors or ARB, the dose of eplerenone will be decreased by 25-50 mg per day. Similarly, patients on monotherapy with eplerenone who develop very high renin concentrations and/or symptomatic hypotension, the dose of eplerenone should be decreased by 25-50 mg per day. Patients who do not attain optimal blood pressure on the maximal eplerenone dose will continue with other antihypertensive medications. It is expected that creatinine will increase in some patients, reflecting diminished renal hyperfiltration that is characteristic for patients with untreated PA. In these cases, the eplerenone dose should not be automatically reduced, and should only be considered in cases with severely worsening GFR (\>1.5 from the baseline value).
Follow-up
Total follow-up time is 24 months. For patients in the MRA arm, there will be a possibility to cross over (opt for surgery) after 12 months. The participants will be followed on at least 7 occasions throughout the study.
Outcome measures
Primary endpoint: The primary endpoint is the difference in improvement of QoL between surgically and medically treated patients at 12 months, measured with EQ5D (total score and the VAS scale).
Secondary endpoints: The secondary endpoints are: 1) Difference in improvement of QoL at 24 months, evaluated with EQ5D, 2) Difference in improvement of QoL at 12 and 24 months, evaluated with the SF-36/RAND-36 questionnaire, 3) The proportion of patients with complete, partial, and absent success of clinical and biochemical outcomes (based on blood pressure, use of antihypertensive drugs, plasma potassium, plasma renin and plasma aldosterone 1) according to the PASO criteria (15) at 12 and 24 months, 4) cardiovascular risk profile at 12 and 24 months, 5) difference in left ventricular mass on echocardiography at 12 and 24 months, 6) difference in renal function, evaluated by measuring eGFR and urinaryalbumin excretion at 12 and 24 months, and 7) total societal cost
Statistics and power calculation
Difference in treatment effects between the two groups will be analysed with paired t-test and Fishers exact test, as well as regression analyses with adjustments for age, gender, duration ofhypertension, as well as blood pressure and number of antihypertensive drugs at baseline.
For power calculation we used quality of life data from Velema et al. (EQ-5D) and Ahmedet al. (RAND SF-36) . With a significance level of 5% and power of 80%, inclusion of 50-54 subjects is needed (25-27 subjects in each treatment arm) to detect a difference betweensurgically and medically treated patients. Allowing for a 20% drop out rate, inclusion is set to 80 subjects (i.e. 40 in each treatment arm).
To ensure external validity, a screening log will be kept at each centre.
Clinical benefits
Contemporary treatment guidelines advocate surgical treatment in patients with unilateral disease. However, since AVS is not always successful, and not widely available, life-long medical treatment is often preferred for patients with PA, without any attempts to find out if they are candidates for curative surgical treatment. It is therefore of great importance to investigate if medical treatment is as effective as surgery in these patients. Currently, a head to head comparison of surgical versus medical treatments for patients with unilateral PA is lacking.
If it turns out that medical treatment is as efficient and safe as surgical treatment for patients with unilateral dominant disease, a large number of patients worldwide will benefit from the study. This concerns patients treated at centres where AVS is not available, patients where the AVS has not been successful as well as patients with unilateral dominant PA who are not considered candidates for surgical intervention. Thus, the study's results have a great potential to be quickly implemented in clinical practice.
Ethical considerations
The main ethical issue to acknowledge is that half of the patients will be randomized to receive medical treatment, i.e. they will not receive surgical treatment that is currently considered to be standard of care for unilateral PA. However, the reasons for considering the trial to be ethical are: a) Medical treatment with mineralocorticoid receptor antagonist forpatients with bilateral PA is effective and safe, b) Thorough information about the study willbe provided before participation, c) Participation is voluntary, d) After 12 months, all medically treated patients will have the option to receive surgical treatment i.e. adrenalectomy.
The study was approved by the Regional Research Ethics Committee in Gothenburg, Sweden on June 3rd, 2020 (DNR 2020-02008).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Hyperaldosteronism Due to Adrenal Adenoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Unblinded, prospective, multi-center,randomized, controlled trial.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Surgically Treated Primary Aldosteronism
Standard therapy
Group Type
ACTIVE_COMPARATOR
Unilateral adrenalectomy
Intervention Type
PROCEDURE
Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
Medically Treated Unilateral Primary Aldosteronism
Open label eplerenone treatment
Group Type
ACTIVE_COMPARATOR
Medical treatment (eplerenone)
Intervention Type
DRUG
The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Unilateral adrenalectomy
Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
Intervention Type
PROCEDURE
Medical treatment (eplerenone)
The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Surgery
Mineralocorticoid receptor antagonists
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients with confirmed unilateral PA
2. Age 18-70 years
3. Candidate for surgical treatment
4. No contraindications for minimally invasive surgery or treatment with MRA
5. Understands oral and written information and provides oral and written informed consent.
2. Age 18-70 years
3. Candidate for surgical treatment
4. No contraindications for minimally invasive surgery or treatment with MRA
5. Understands oral and written information and provides oral and written informed consent.
Exclusion Criteria
1. Unwilling or unable to undergo surgery
2. Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)
3. Impaired renal function with eGFR \<45 ml/min/1,73m2
4. P-cortisol \>138 nmol/L following 1-mg overnight dexamethasone suppression test.
2. Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)
3. Impaired renal function with eGFR \<45 ml/min/1,73m2
4. P-cortisol \>138 nmol/L following 1-mg overnight dexamethasone suppression test.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Sponsor Role
collaborator
Umeå University
OTHER
Sponsor Role
collaborator
Göteborg University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oskar Ragnarsson
MD, PHD, Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oskar Ragnarsson, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Gothenburg
Gothenburg, , Sweden
Site Status
RECRUITING
Karolinska University Hospital, Stockholm, Sweden.
Stockholm, , Sweden
Site Status
NOT_YET_RECRUITING
Umeå University, Umeå, Sweden.
Umeå, , Sweden
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019 Feb;285(2):126-148. doi: 10.1111/joim.12831. Epub 2018 Sep 25.
Reference Type
BACKGROUND
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820. doi: 10.1016/j.jacc.2017.01.052.
Reference Type
BACKGROUND
Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9.
Reference Type
BACKGROUND
Muth A, Ragnarsson O, Johannsson G, Wangberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg. 2015 Mar;102(4):307-17. doi: 10.1002/bjs.9744. Epub 2015 Jan 20.
Reference Type
BACKGROUND
Huang WC, Chen YY, Lin YH, Chueh JS. Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis. Front Endocrinol (Lausanne). 2021 May 17;12:644260. doi: 10.3389/fendo.2021.644260. eCollection 2021.
Reference Type
BACKGROUND
Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011 Sep;96(9):2904-11. doi: 10.1210/jc.2011-0138. Epub 2011 Jul 21.
Reference Type
BACKGROUND
Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, Schultze Kool L, Langenhuijsen J, Prejbisz A, van der Wilt GJ, Deinum J; SPARTACUS investigators. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab. 2018 Jan 1;103(1):16-24. doi: 10.1210/jc.2017-01442.
Reference Type
BACKGROUND
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59. doi: 10.1016/S2213-8587(17)30367-4. Epub 2017 Nov 9.
Reference Type
BACKGROUND
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.
Reference Type
BACKGROUND
Zhou Y, Wang D, Jiang L, Ran F, Chen S, Zhou P, Wang P. Diagnostic accuracy of adrenal imaging for subtype diagnosis in primary aldosteronism: systematic review and meta-analysis. BMJ Open. 2020 Dec 31;10(12):e038489. doi: 10.1136/bmjopen-2020-038489.
Reference Type
BACKGROUND
Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, Seufert J, Quinkler M, Bidlingmaier M, Beuschlein F, Endres S, Reincke M. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int. 2009 May;106(18):305-11. doi: 10.3238/arztebl.2009.0305. Epub 2009 May 1.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DNR 2020-02008
Identifier Type: OTHER
Identifier Source: secondary_id
ALFGBG-978940
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT03760835
RECRUITING
PHASE4
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
NCT06801249
RECRUITING
PHASE4
Biomarker(s) for Glucocorticoids
NCT02152553
COMPLETED
NA
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
NCT07268222
RECRUITING
PHASE4
Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome
NCT01246739
TERMINATED
NA
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01794793
COMPLETED
PHASE4
Glucocorticoid Treatment in Addison's Disease
NCT01063569
COMPLETED
PHASE2/PHASE3
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas
NCT04917757
ACTIVE_NOT_RECRUITING
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
NCT00488124
COMPLETED
PHASE2
Self-management in Patients With Adrenal Insufficiency.
NCT06637722
ACTIVE_NOT_RECRUITING
The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation
NCT00688987
COMPLETED
NA
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
NCT06955286
RECRUITING
Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)
NCT02277587
COMPLETED
PHASE4
Androgen Reduction in Congenital Adrenal Hyperplasia
NCT03548246
WITHDRAWN
PHASE2
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
NCT04308590
COMPLETED
PHASE3
Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors
NCT06679816
RECRUITING
PHASE4
Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia
NCT00529841
COMPLETED
NA
Does Relative Hypoglycaemia &/or Sleep Disturbance Contribute to the Lethargy Observed in Addison's Disease
NCT05515055
UNKNOWN
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
NCT00805753
COMPLETED
PHASE1
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00376064
COMPLETED
PHASE4
Adrenal Function in GHD Children
NCT03203356
COMPLETED
A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)
NCT03210545
COMPLETED
PHASE4
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
NCT00001521
COMPLETED
PHASE3
COrticosteroid in Congenital Adrenal Hyperplasia
NCT02552251
UNKNOWN
PHASE2/PHASE3